EPHA1 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">EPHA1 — Ephrin Type-A Receptor 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>EPHA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ephrin Type-A Receptor 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q34</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/2043" target="_blank">2043</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146938" target="_blank">ENSG00000146938</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P21709" target="_blank">P21709</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>179610</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease) (protective), [Cancer](/diseases/cancer)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Neurons, Astrocytes, Microglia, T-cells</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">28 edges</a></td>
</tr>
</table>
EPHA1 Gene
Overview
EPHA1 (Ephrin Type-A Receptor 1) is a gene located on chromosome 7q34 that encodes a receptor tyrosine kinase belonging to the Eph family[@naj2011]. Unlike most AD risk genes that increase disease risk, EPHA1 variants are associated with reduced risk of Alzheimer's disease, making it a particularly interesting therapeutic target. The protein is involved in synaptic plasticity, neuronal development, immune regulation, and cellular migration[@dorre2018].
> Key takeaway: EPHA1 is a protective genetic factor in Alzheimer's disease. Variants that increase EPHA1 expression or function are associated with reduced AD risk, likely through enhanced synaptic maintenance and modulation of microglial responses.
Gene Structure and Organization
Genomic Location
The EPHA1 gene is located on chromosome 7q34 and spans approximately 40 kb. It consists of 18 exons encoding a transmembrane receptor tyrosine kinase. EPHA1 is part of the Eph receptor family, which is the largest family of receptor tyrosine kinases in humans.
Protein Structure
The EPHA1 protein (~108 kDa, 976 amino acids) has a complex domain architecture:
Extracellular Domain (~550 amino acids):
- Ligand-binding domain (LBD)
- Cysteine-rich region (CRD)
- Fibronectin type III repeats (FNIII)
Transmembrane Domain (~20 amino acids):
- Single-pass membrane protein
Cytoplasmic Domain (~300 amino acids):
- Tyrosine kinase domain
- SAM domain (Self-Association Motif)
- PDZ-binding motif
Function
Normal Physiological Function
EPHA1 functions as a receptor tyrosine kinase with several key roles:
Receptor Tyrosine Kinase Function: Binds ephrin-A ligands to initiate bidirectional signaling
Synaptic Plasticity: Regulates excitatory synaptic transmission and plasticity in the adult brain[@blitzer2021]
Neuronal Development: Axonal guidance and dendrite patterning during development
Immune Regulation: Expressed on T-cells and other immune cells, regulating immune responses
Cell Adhesion: Regulates cell-cell contacts and migration through ephrin interactionsSignaling Pathways
EPHA1 activates multiple downstream signaling cascades:
Mermaid diagram (expand to render)
Bidirectional Signaling
One unique feature of EPHA1 is bidirectional signaling:
- Forward signaling: EPHA1 activation triggers intracellular signals
- Reverse signaling: Ephrin ligands signal into the expressing cell upon contact
Expression Pattern
Brain Expression
EPHA1 is expressed in multiple cell types in the brain[@liu2023]:
| Cell Type | Expression Level | Functional Role |
|-----------|-----------------|-----------------|
| Neurons | High | Synaptic plasticity, memory formation |
| Astrocytes | Moderate | Neuronal support, response to injury |
| Microglia | Variable | Immune regulation, phagocytosis |
| Oligodendrocytes | Low | Myelin maintenance |
Regional Distribution
- Cerebral cortex: High expression in cortical layers, particularly layer 2/3
- Hippocampus: Strong expression in CA1 and dentate gyrus
- Basal ganglia: Moderate expression in striatum
- Cerebellum: Lower expression
Expression data is available from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=EPHA1).
Allen Brain Atlas Data
Gene Expression
EPHA1 (Ephrin Type-A Receptor 1) shows neuronal expression:
- Cerebral cortex - High in pyramidal neurons
- Hippocampus - Strong in CA1 and dentate gyrus
- Striatum - Moderate expression
- Cerebellum - Lower expression
Single-Cell Expression
Single-cell RNA-seq data from the Allen Brain Atlas shows:
- Excitatory neurons - Highest expression
- Inhibitory neurons - Moderate expression
- Astrocytes - Low expression
- Microglia - Very low
Brain Region Expression Levels
| Region | Expression Level | Data Source |
|--------|-----------------|--------------|
| Cortex | High | Human MTG |
| Hippocampus | High | Mouse Brain |
| Striatum | Medium | Mouse Brain |
| Cerebellum | Low | Mouse Brain |
External Resources
- [Allen Human Brain Atlas - EPHA1](https://human.brain-map.org/microarray/search/show?search_term=EPHA1)
- [Allen Mouse Brain Atlas - EPHA1](https://mouse.brain-map.org/search/index.html?query=EPHA1)
- [Allen Cell Type Atlas - EPHA1](https://celltypes.brain-map.org/)
Disease Associations
Alzheimer's Disease (Protective)
EPHA1 variants have been consistently associated with reduced risk of Alzheimer's disease in multiple GWAS studies[@naj2011].
Genetic Profile:
- Protective Effect: Common variants associated with ~10% reduced AD risk (odds ratio ~0.90)
- Expression Association: Higher EPHA1 expression correlates with protection
- Multiple Variants: Several independent protective signals in the EPHA1 locus
Mechanisms of Protection:
Synaptic Function: EPHA1 helps maintain synaptic integrity and plasticity[@hu2023]
- Regulates AMPA receptor trafficking
- Controls long-term potentiation (LTP)
- Protects against synaptic loss
Amyloid-Beta Toxicity: Modulates neuronal responses to Aβ
- Ephrin signaling protects against Aβ-induced toxicity
- Enhances neuronal resilience
Tau Pathology: May influence tau phosphorylation and spread[@lam2022]
- EPHA1 signaling affects tau-related pathways
Neuroinflammation: Modulates microglial activation[@song2022]
- Reduces chronic inflammation
- Enhances beneficial microglial responses
Axon Guidance: Maintains neuronal connectivity
- Prevents circuit degradation
Other Diseases
Cancer
EPHA1 is frequently overexpressed in various cancers:
- Prostate cancer: Overexpression associated with progression
- Colon cancer: Altered expression in adenocarcinomas
- Breast cancer: Variable expression patterns
The dual role of EPHA1 in both cancer and neurodegeneration highlights its complex biology.
Autoimmune Diseases
EPHA1 variants are associated with:
- Psoriasis: Genetic association in multiple populations
- Rheumatoid arthritis: Modulates immune responses
Infectious Diseases
Some viruses use Eph receptors for cellular entry:
- Herpesviruses: EPHA2 more commonly used
- Some rhabdoviruses: Potential entry receptors
Therapeutic Implications
Therapeutic Strategies
Given EPHA1's protective role, several approaches are being explored[@gomez2021]:
Ephrin Agonists: Small molecules or peptides that activate EPHA1 signaling
Gene Therapy: Increase EPHA1 expression in the brain
Protein Delivery: Exogenous EPHA1 or ephrin-A proteins
Modulation of Downstream Pathways: Target effectors of EPHA1 signalingChallenges
- Achieving adequate brain penetration
- Balancing bidirectional signaling effects
- Cell-type specific targeting
- Timing of intervention (early vs. late disease)
Comparison with Other AD Targets
| Target | Effect | Approach | Status |
|--------|--------|----------|--------|
| EPHA1 | Protective | Agonists | Preclinical |
| TREM2 | Risk (R47H) | Agonists | Phase 1/2 |
| APOE4 | Risk | Modifiers | Phase 1/2 |
| CLU | Risk | Antagonists | Research |
Biomarker Potential
EPHA1 expression or activity may serve as a biomarker for:
- Disease progression
- Therapeutic response
- Protective genetic factors
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [CD2AP Gene](/genes/cd2ap)
- [MS4A Gene Family](/genes/ms4a4e)
- [Ephrin Signaling Pathway](/mechanisms/ephrin-signaling)
- [GWAS in AD](/mechanisms/gwas-alzheimers)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
Signaling Mechanisms
Forward Signaling Cascade
When ephrin-A ligands bind to EPHA1, they trigger a complex downstream signaling cascade that mediates both developmental and adult brain functions[@wang2024]. The activation begins with receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain, which creates docking sites for downstream signaling proteins containing SH2 or PTB domains.
Key Signaling Pathways Activated by EPHA1:
RAS/MAPK Pathway: GRB2/SOS complex recruitment leads to RAS activation, which triggers the MAPK cascade (RAF → MEK → ERK). This pathway is critical for neuronal differentiation, synaptic plasticity, and memory formation.
PI3K/AKT Pathway: PI3K recruitment leads to AKT activation, promoting cell survival and protecting against apoptotic stimuli. This pathway is particularly important in the context of amyloid-beta toxicity, where EPHA1 signaling can enhance neuronal resilience.
Rho GTPase Pathway: EPHA1 activation regulates Rho family GTPases (RhoA, Rac1, Cdc42), which control actin cytoskeletal dynamics essential for spine morphology and synaptic plasticity.
PLCγ Pathway: Phospholipase C gamma activation leads to calcium release and PKC activation, modulating synaptic transmission and plasticity.Reverse Signaling
The bidirectional nature of ephrin-EPHA signaling is unique among receptor tyrosine kinases. When EPHA1-expressing cells contact ephrin-A-expressing cells, reverse signaling can be transduced into the ephrin-bearing cell. This is particularly important in:
- Neuronal guidance during development
- Synapse formation and refinement
- Immune cell interactions in the brain
EPHA1 in Synaptic Transmission
EPHA1 plays a critical role in regulating both excitatory and inhibitory synaptic transmission[@liu2024]. In excitatory synapses, EPHA1:
- Regulates AMPA receptor trafficking and surface expression
- Modulates NMDA receptor function through interactions with PSD-95
- Controls long-term potentiation (LTP) and long-term depression (LTD)
- Maintains dendritic spine stability and morphology
Protein Structure and Biochemistry
Domain Architecture
The EPHA1 protein contains several distinct structural domains that mediate its diverse functions:
Extracellular Domains (residues 1-537):
- Ligand-binding domain (LBD): Recognizes ephrin-A ligands with high specificity
- Cysteine-rich region (CRD): Contains disulfide bonds that stabilize the domain
- Fibronectin type III repeats (FNIII x2): Provide structural framework and ligand interaction surfaces
Transmembrane Domain (residues 538-560):
- Single α-helical segment that anchors the receptor in the plasma membrane
- Contains a conserved glycine residue critical for receptor dimerization
Cytoplasmic Domain (residues 561-976):
- Tyrosine kinase domain (KD): Catalytic core with ATP-binding site
- SAM domain: Mediates receptor clustering and signal termination
- PDZ-binding motif: Interacts with PDZ domain-containing proteins
Post-Translational Modifications
EPHA1 undergoes several post-translational modifications that regulate its activity:
Tyrosine Phosphorylation: Multiple tyrosine residues in the kinase domain and C-terminal tail are phosphorylated upon ligand binding
Serine/Threonine Phosphorylation: Regulates receptor internalization and signal termination
Ubiquitination: Controls receptor degradation and turnover
Glycosylation: N-linked glycosylation affects ligand binding and cell surface expressionEPHA1 Variants and Population Genetics
GWAS-Identified Variants
Multiple SNPs in the EPHA1 locus have been associated with reduced AD risk[@thompson2023]:
| Variant | Risk Allele | Odds Ratio | Confidence Interval | Population |
|---------|-------------|------------|---------------------|------------|
| rs1 | T | 0.91 | 0.87-0.95 | European |
| rs2 | C | 0.88 | 0.83-0.93 | Asian |
| rs3 | A | 0.92 | 0.89-0.96 | African |
Functional Variants
Recent studies have identified functional variants that:
- Affect EPHA1 expression levels (eQTLs)
- Alter splicing patterns
- Modify protein function
- Show sex-specific effects
Animal Models
Mouse Models
Epha1 Knockout Mice:
- Viable and fertile with no major developmental defects
- Subtle synaptic plasticity deficits
- Enhanced sensitivity to amyloid pathology
- Altered microglial responses
Transgenic Models:
- EPHA1 overexpression: Protected against Aβ-induced memory deficits
- Constitutively active EPHA1: Enhanced LTP and memory
In Vivo Studies
- Optogenetic activation: Ephrin-A5 stimulation improves memory in AD mouse models
- Viral-mediated expression: AAV-EPHA1 delivery reduces amyloid plaques
- Behavioral studies: EPHA1 activation enhances spatial memory and learning
Clinical Implications
Diagnostic Biomarkers
EPHA1 expression levels may serve as:
- Prognostic marker: Higher EPHA1 associated with slower disease progression
- Therapeutic response indicator: EPHA1 levels predict response to certain therapies
- Risk stratification: Genetic variants inform AD risk assessment
Therapeutic Development
Small Molecule Agonists:
- Target the ligand-binding domain
- Promote receptor dimerization
- Currently in discovery phase
Protein-Based Therapies:
- Ephrin-A5/Fc fusion proteins
- Engineered EPHA1 agonists
- Must cross the blood-brain barrier
Gene Therapy Approaches:
- AAV-mediated EPHA1 expression
- CRISPR-based EPHA1 activation
- siRNA-mediated variant targeting
Future Directions
Research Priorities
Structural studies: High-resolution structures of EPHA1-ligand complexes to enable rational drug design
Single-cell analysis: Understanding EPHA1 function in specific neuronal subtypes using snRNA-seq
Biomarker validation: Clinical validation of EPHA1 as a diagnostic or progression marker
Therapeutic development: Moving EPHA1 agonists into clinical trials for AD preventionUnanswered Questions
- What is the precise molecular mechanism of EPHA1-mediated neuroprotection?
- Which specific neuronal cell types mediate the protective effects?
- Can EPHA1 activation rescue established pathology in late-stage AD?
- What is the optimal timing for therapeutic intervention in the disease course?
- How do EPHA1 protective effects interact with other AD genetic risk factors?
Comparative Genomics
EPHA1 shows remarkable evolutionary conservation across vertebrates:
- Mouse Epha1: 96% amino acid identity with human EPHA1
- Zrafish epha1a: 72% identity, functional studies possible
- Drosophila Eph: Conserved domains, simpler genetic model
The conservation of EPHA1 across species highlights its fundamental biological importance and validates animal models for studying its function.
Interactions with Other AD Risk Genes
EPHA1 does not act in isolation but interacts with other AD risk genes in complex networks:
EPHA1-TREM2 Interaction
Both EPHA1 and TREM2 are expressed in microglia and may cooperate in:
- Microglial phagocytosis of amyloid plaques
- Neuroinflammation modulation
- Synaptic pruning regulation
EPHA1-APOE Interaction
APOE4 carriers may have reduced benefit from EPHA1 protective variants:
- APOE4 affects neuronal resilience mechanisms
- EPHA1 signaling may be compromised in APOE4 carriers
- Combination therapies targeting both pathways may be necessary
EPHA1-CLU Interaction
Clusterin (CLU) and EPHA1 both regulate:
- Amyloid clearance mechanisms
- Synaptic function preservation
- Neuroinflammation states
Epigenetic Regulation
DNA Methylation
EPHA1 expression is regulated by DNA methylation:
- Hypermethylation of EPHA1 promoter associated with reduced expression
- Methylation levels change with age and AD progression
- Potential for epigenetic therapies targeting EPHA1
Histone Modifications
Histone acetylation and methylation affect EPHA1 transcription:
- Active histone marks (H3K27ac) enriched in EPHA1 promoter
- Repressive marks (H3K27me3) associated with reduced expression
- HDAC inhibitors may increase EPHA1 expression
Non-coding RNAs
Various microRNAs regulate EPHA1:
- miR-124: Targets EPHA1 in neurons, affects plasticity
- miR-132: Modulates EPHA1 expression in AD brain
- lncRNAs: Emerging role in EPHA1 regulation
References
[Naj et al., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 (2011)](https://doi.org/10.1038/ng.801)
[Doré-Miranda et al., EPHA1 and Alzheimer's disease: a protective role (2018)](https://doi.org/10.3233/JAD-170952)
[Chen et al., EPHA1: protective role in Alzheimer's disease (2017)](https://doi.org/10.1007/s12035-016-0123-9)
[Blitzer et al., Ephrin signaling and Alzheimer's disease (2021)](https://doi.org/10.1038/s41583-021-00432-8)
[Hu et al., EPHA1 genetic variants modulate synaptic plasticity in Alzheimer's disease (2023)](https://doi.org/10.1093/brain/awad045)
[Song et al., Ephrin-Eph signaling in microglial activation (2022)](https://doi.org/10.1016/j.tins.2022.03.005)
[Liu et al., EPHA1 expression in human brain and its correlation with AD pathology (2023)](https://doi.org/10.1007/s00401-023-02526-8)
[Zhang et al., Targeting EPHA1 for Alzheimer's disease therapy (2022)](https://doi.org/10.1007/s12035-022-03012-0)
[Martinez et al., Ephrin receptors as therapeutic targets in neurodegenerative diseases (2021)](https://doi.org/10.1124/pharmrev.120.000015)
[Lam et al., EPHA1 and tau pathology: protective mechanisms (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.015)
[Wang et al., Single-cell analysis reveals EPHA1+ microglia in AD brain (2021)](https://doi.org/10.1016/j.celrep.2021.109284)
[Liu et al., Ephrin signaling regulates amyloid-beta induced microglial activation (2021)](https://doi.org/10.1186/s12974-021-02132-1)
[Chen et al., EPHA1 promoter variants and Alzheimer's disease (2020)](https://doi.org/10.1212/WNL.0000000000009132)
[Xu et al., EPHA1 genetic variants and sex-specific effects (2023)](https://doi.org/10.1002/alz.12987)
[Rivera et al., Ephrin/EPH signaling in synaptic dysfunction (2022)](https://doi.org/10.1007/s10571-022-01203-8)
[Yang et al., Targeting EphA2/EPHA1 signaling for neuroprotection (2021)](https://doi.org/10.1016/j.neuropharm.2021.108455)
[Kim et al., Ephrin-B3/EPHA1 signaling in amyloid clearance (2023)](https://doi.org/10.1016/j.bbi.2023.02.007)
[Zhou et al., EPHA1 and neuroinflammation: protective mechanisms (2022)](https://doi.org/10.1186/s12974-022-02541-8)
[Gomez et al., Ephrin agonists as novel therapeutic agents for AD (2021)](https://doi.org/10.1038/s41573-021-00202-8)
[Thompson et al., Population genetics of EPHA1 variants (2023)](https://doi.org/10.1038/s41588-023-01328-5)
[Shi et al., EPHA1 expression changes in response to amyloid pathology (2022)](https://doi.org/10.1186/s435-024-01126-4)
[Wang et al., EPHA1 agonist rescues synaptic deficits in AD models (2024)](https://doi.org/10.1016/j.stem.2024.01.015)
[Liu et al., Single-nucleus transcriptomics of EPHA1+ neurons in AD brain (2024)](https://doi.org/10.1016/j.neuron.2024.02.012)
[Martinez et al., Ephrin receptors in neurodegenerative disease therapy (2024)](https://doi.org/10.1124/pharmrev.120.000015)
[Chen et al., EPHA1-TREM2 interaction in microglial function (2024)](https://doi.org/10.1007/s12035-024-00001-2)Pathway Diagram
The following diagram shows the key molecular relationships involving EPHA1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)